共 9 条
[1]
et al.Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. Ducharme A,Frantz S,Aikawa M. The Journal of Clinical Investigation . 2000
[2]
Latenttransforminggrowthfactor betabindingproteins(LTBPs)———structuralextracellularmatrixproteinsfortargetingTGF betaaction. SaharinenJ,HyytiainenM,TaipaleJ, etal. CytokineGrowthFactorRev . 1999
[3]
Myocardial matrix degradation and metalloproteinase activation in the failing heart : a potential therapeutic target. Spinale FG,Coker ML,Bond BR,et al. Cardiovascular Research . 2000
[4]
Heart failure[P]. 英国专利:GB202507839D0,2025-07-02
[5]
Evolution of matrix metalloproteinase and tissue inhibitor expression during heart failure progression int infracted rat. Peterson JT,Li H,Dillon L,et al. Cardiovascular Research . 2000
[6]
Effects of gene diletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in Mice. Roten L,Nemoto S,Simsic J,et al. Journal of Molecular and Cellular Cardiology . 2000
[7]
Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Nagahiro N,Kazuhiro Y,Yasushi S,et al. Cardiovascular Research . 2003
[8]
Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Li YY,Feldman AM,Sun Y,et al. Circulation . 1998
[9]
Inhibition of plasminogen activators or matrix metallproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Heymans S,Luttun A,Nuyens D,et al. Nature Medicine . 1999